ES015 / Elpiscience - LARVOL DELTA

A NKG2A antibody-IL-2 mutant fusion protein for cancer immunotherapy (SITC 2024) - "Mouse surrogate ES015-IL2m antibody enhances the intra-tumoral NKG2A+ NK and CD8 T cell proliferation/activation and has superior control of malignancies in vivo. Conclusions In summary, ES015-IL2v is a highly potent anti-tumor agent, and our in vitro and in vivo data support its further development into next stage."

IO biomarker • Hematological Malignancies • Oncology • CD8 • FCGR2A • FCGR2B • HLA-E • IL2 • IL2RG • KLRC1

A NKG2A antibody-IL-2 mutant fusion protein for cancer immunotherapy (SITC 2024) - "Mouse surrogate ES015-IL2m antibody enhances the intra-tumoral NKG2A+ NK and CD8 T cell proliferation/activation and has superior control of malignancies in vivo. Conclusions In summary, ES015-IL2v is a highly potent anti-tumor agent, and our in vitro and in vivo data support its further development into next stage."

IO biomarker • Hematological Malignancies • Oncology • CD8 • FCGR2A • FCGR2B • HLA-E • IL2 • IL2RG • KLRC1

Elpiscience Announces Studies Presented at Society for Immunotherapy of Cancer (SITC) 2023 Annual Meeting (Businesswire) - "Elpiscience Biopharmaceuticals...presented studies for its innovative immunotherapeutic molecules at the SITC 2023 Annual Meeting....Our study showed that ES014, a bifunctional antibody–ligand trap which comprises an antibody targeting CD39 fused to a TGFβ receptor II ectodomain, can inhibit TGFβ activity and lead to cancer killing in ex vivo models....ES015-2 can completely block the interaction of NKG2A/CD94 with HLA-E, thereby inhibits HLA-E-induced NKG2A inhibitory signaling. Ligation of ES015-2 effectively potentiates the activation of NKG2C+ NK cells and T cells....ES008-a promotes NK cell-mediated destruction of tumor cells. ES008-a synergizes with CD47/SIRPα inhibitors in enhancing macrophage phagocytosis of tumor cells."

Preclinical • Oncology

ES015, a first-in-class NKG2A and NKG2C dual-targeting antibody, demonstrated potent anti-tumor immune response (SITC 2023) - "Our preclinical data suggested that dual target of NKG2A and NKG2C is more efficacious than targeting NKG2A alone. The dual targeting agent ES015, once entering the clinical trials, is hence expected to demonstrate superior clinical response in clinical trials."

IO biomarker • Oncology • CD8 • HLA-E • KLRC1

Elpiscience Announces Three Poster Presentations at Society for Immunotherapy of Cancer (SITC) 2023 Annual Meeting (Businesswire) - "Elpiscience Biopharmaceuticals...announced it will have three poster presentations at the SITC 2023 Annual Meeting taking place November 3-5, 2023, in San Diego. The posters will highlight its studies on three innovative molecules including a first-in-class NKG2A/NKG2C dual-targeting antibody ES015, a high affinity LILRB1 specific blocking antibody ES008-a, and the first-in-class anti-CD39/TGF-βRII bifunctional fusion protein ES014 which has been proven to be able to deliver TGFβ 'trap' to CD39-expressing immune and stroma cells to reshape tumor microenvironment and rejuvenates antitumor immunity."

Preclinical • Oncology